OnKure Therapeutics (OKUR) Stock Analysis
NASDAQHealthcareBiotechnology
What OnKure Therapeutics does
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Key metrics
ETFs linked to OKUR
Broad-market and Healthcare sector ETFs an investor holding OnKure Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how OKUR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze OKUR in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for OnKure Therapeutics?
- OnKure Therapeutics trades under the ticker OKUR on NASDAQ.
- Which exchange is OKUR listed on?
- OKUR is listed on NASDAQ.
- What sector does OnKure Therapeutics operate in?
- OnKure Therapeutics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze OKUR in a portfolio?
- PortView shows OKUR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.